Trametinib plus dabrafenib: Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma
10.2122/gbc.2012.0251
Saved in:
Main Author: | Ku, C.-S. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Review |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/116896 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
by: Meevassana J.
Published: (2023) -
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
by: Michael T. Tetzlaff, et al.
Published: (2018) -
Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202
by: Porntipa Korprasertthaworn, et al.
Published: (2020) -
Detection of BRAF V600E mutation by pyrosequencing
by: Tan, Y.H., et al.
Published: (2012) -
Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas
by: Puangwan Lapthanasupkul, et al.
Published: (2020)